10x Genomics, Inc.
TXG
Rank in Stocks
#2212
Headquartered in Pleasanton, California, 10x Genomics, Inc. (founded in 2012... Headquartered in Pleasanton, California, 10x Genomics, Inc. (founded in 2012 and known as 10X Technologies, Inc. until November 2014) is a prominent life science technology company. The firm specializes in creating and distributing sophisticated instrumentation, essential consumables, and software designed for in-depth analysis of biological systems. Its market presence extends globally, covering North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company's offerings feature Chromium and Chromium Connect instruments, supported by indispensable items such as microfluidic chips, slides, and reagents. A significant portion of their portfolio focuses on single-cell solutions, leveraging their Chromium platforms. These allow for precise measurement of gene activity at the individual cell level (single cell gene expression), detailed assessment of immune cell function and their targets (single cell immune profiling), exploration of DNA's physical organization and epigenetic modifications (single cell Assay for Transposase Accessible Chromatin - ATAC), and the concurrent quantification of both genetic activity and epigenetic programming across tens of thousands of cells in a single experiment (single cell multiome ATAC + gene expression). Additionally, 10x Genomics offers the Visium spatial gene expression solution, which maps gene activity patterns within specific tissue sections and can also facilitate co-detection of gene expression and proteins when paired with immunofluorescence. Their varied customer base includes academic, governmental, biopharmaceutical, and biotechnology organizations, among others.
Share Price
$70.28
Market Cap
$9.16B
Change (1 day)
0.60%
Change (1 year)
494.07%
Country
US
Trade 10x Genomics, Inc. (TXG)
Category
Healthcare
P/E ratio for 10x Genomics, Inc. (TXG)
P/E ratio as of October 2026 TTM: -123.90
According to 10x Genomics, Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -123.90. At the end of 2023 the company had a P/E ratio of -25.70.
P/E ratio history for 10x Genomics, Inc. from 2017 to 2026
P/E ratio at the end of each year
| Year | P/E Ratio | Change |
|---|---|---|
| 2026 (TTM) | -123.90 | 1,208.32% |
| 2024 | -9.47 | -63.15% |
| 2023 | -25.70 | 2.83% |
| 2022 | -24.99 | -91.15% |
| 2021 | -282.32 | 969.76% |
| 2020 | -26.39 | -72.31% |
| 2019 | -95.31 | 1,417.64% |
| 2018 | -6.28 | -80.72% |
| 2017 | -32.58 | 0.00% |
P/E ratio for similar companies or competitors
| Company | P/E Ratio | P/E Ratio Difference | Country |
|---|---|---|---|
| 19.68 | -115.88% |
US
|
|
| 64.40 | -151.98% |
AU
|
|
| 44.30 | -135.76% |
US
|
|
| -47.78 | -61.44% |
US
|
|
| - | - |
US
|
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.